Literature DB >> 31180050

Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients.

Shicong Tang1, Kai Zheng, Yiyin Tang, Zhen Li, Tianning Zou, Dequan Liu.   

Abstract

To investigate the source of serum exosomal HOTAIR, to uncover the diagnostic and prognostic values of serum exosomal HOTAIR, and to discern the expression of serum exosomal HOTAIR between neoadjuvant chemotherapy and response to tamoxifen therapy. Samples were collected from the Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan. Exosomes were isolated from serum, cell culture medium and tumor tissues. We used transmission electron microscopy and western immunoblotting assay to characterize exosomes, and real-time PCR (qPCR) to assess HOTAIR expression. Neoadjuvant chemotherapy and tamoxifen therapy were carried out according to established guidelines. Breast cancer patients expressed higher serum exosomal HOTAIR than did healthy individuals (P\0.001). Serum exosomal HOTAIR levels 3 months after surgery were markedly decreased compared with levels before surgery (P\0.001), and the expression level of exosomal HOTAIR in cell culture medium increased with time in both breast cancer cell lines (72 h greater than 48 h greater than 24 h, 48 h vs 24 h [ [P less than 0.05]; 72 h vs 24 h [P less than 0.01]. Expression of serum exosomal HOTAIR in nude mice was notably greater than in the mock control group (P less than 0.001). The results of the ROC analysis revealed an AUC for serum exosomal HOTAIR of 0.9178 with a 95% CI of 0.8407-1.017 (P less than 0.01). The AUC for the CA15-3 cell line was 0.7378 (95% CI, 0.5585-0.9170; P = 0.03). High expression of exosomal HOTAIR led to a worse disease-free survival (P = 0.0481) and overall survival (P = 0.0463). In the high-expression chemotherapy group, six patients achieved a partial response (PR) and eight demonstrated stable disease (SD) and nine patients achieved PR and two SD in the low-expression group (P = 0.048). In the low-expression tamoxifen group, one patient had a recurrence of breast cancer and another 10 patients exhibited no recurrence, while six showed recurrence, and seven had none in the highexpression group (P = 0.035). We isolated exosomes successfully, and demonstrated that serum exosomal HOTAIR originated from primary breast cancer tissue. We conclude that serum exosomal HOTAIR exhibits the potential to be a diagnostic and prognostic biomarker. High expression of serum exosomal HOTAIR was also correlated with poor neoadjuvant chemotherapy and response to tamoxifen therapy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31180050

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  41 in total

1.  Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.

Authors:  John L Rinn; Michael Kertesz; Jordon K Wang; Sharon L Squazzo; Xiao Xu; Samantha A Brugmann; L Henry Goodnough; Jill A Helms; Peggy J Farnham; Eran Segal; Howard Y Chang
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

Review 2.  Epigenetic regulation by long noncoding RNAs.

Authors:  Jeannie T Lee
Journal:  Science       Date:  2012-12-14       Impact factor: 47.728

3.  Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.

Authors:  Zhe Yang; Lin Zhou; Li-Ming Wu; Ming-Chun Lai; Hai-Yang Xie; Feng Zhang; Shu-Sen Zheng
Journal:  Ann Surg Oncol       Date:  2011-02-15       Impact factor: 5.344

Review 4.  Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling.

Authors:  James W Dear; Jonathan M Street; Matthew A Bailey
Journal:  Proteomics       Date:  2013-02-15       Impact factor: 3.984

Review 5.  Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity.

Authors:  Massimo Stefani
Journal:  Neuroscientist       Date:  2007-10       Impact factor: 7.519

6.  Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration.

Authors:  Valbona Luga; Liang Zhang; Alicia M Viloria-Petit; Abiodun A Ogunjimi; Mohammad R Inanlou; Elaine Chiu; Marguerite Buchanan; Abdel Nasser Hosein; Mark Basik; Jeffrey L Wrana
Journal:  Cell       Date:  2012-12-21       Impact factor: 41.582

7.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Dana W Y Tsui; Davina Gale; Tim Forshew; Anna M Piskorz; Christine Parkinson; Suet-Feung Chin; Zoya Kingsbury; Alvin S C Wong; Francesco Marass; Sean Humphray; James Hadfield; David Bentley; Tan Min Chin; James D Brenton; Carlos Caldas; Nitzan Rosenfeld
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

8.  Effect of three decades of screening mammography on breast-cancer incidence.

Authors:  Archie Bleyer; H Gilbert Welch
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

9.  Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.

Authors:  Rajnish A Gupta; Nilay Shah; Kevin C Wang; Jeewon Kim; Hugo M Horlings; David J Wong; Miao-Chih Tsai; Tiffany Hung; Pedram Argani; John L Rinn; Yulei Wang; Pius Brzoska; Benjamin Kong; Rui Li; Robert B West; Marc J van de Vijver; Saraswati Sukumar; Howard Y Chang
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

10.  Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma.

Authors:  Karen M Chisholm; Yue Wan; Rui Li; Kelli D Montgomery; Howard Y Chang; Robert B West
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

View more
  22 in total

Review 1.  Emerging Role of Exosomal-Derived Long Noncoding RNAs in Human PDAC.

Authors:  Di Long; Xiao Dong Tian; Yin-Mo Yang
Journal:  Visc Med       Date:  2021-12-20

Review 2.  Extracellular vesicles and particles impact the systemic landscape of cancer.

Authors:  Serena Lucotti; Candia M Kenific; Haiying Zhang; David Lyden
Journal:  EMBO J       Date:  2022-09-02       Impact factor: 14.012

Review 3.  Long Non-Coding RNA in the Pathogenesis of Cancers.

Authors:  Yujing Chi; Di Wang; Junpei Wang; Weidong Yu; Jichun Yang
Journal:  Cells       Date:  2019-09-01       Impact factor: 6.600

Review 4.  The HOTAIR lncRNA: A remarkable oncogenic promoter in human cancer metastasis.

Authors:  Lili Chen; Xinle Qian; Zhongqi Wang; Xiqiu Zhou
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

Review 5.  Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies.

Authors:  Marta Tellez-Gabriel; Erik Knutsen; Maria Perander
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

Review 6.  The Role of Exosomes in the Female Reproductive System and Breast Cancers.

Authors:  Yuqi Bai; Jie Guo; Zhongshan Liu; Yunfeng Li; Shunzi Jin; Tiejun Wang
Journal:  Onco Targets Ther       Date:  2020-12-08       Impact factor: 4.147

Review 7.  The Role of Tumor-Derived Exosomes in the Abscopal Effect and Immunotherapy.

Authors:  Zechen Shan; Hongmei Wang; Yujuan Zhang; Weiping Min
Journal:  Life (Basel)       Date:  2021-04-23

Review 8.  Current Knowledge of Long Non-Coding RNA HOTAIR in Breast Cancer Progression and Its Application.

Authors:  Yubo Shi; Qingyun Huang; Xinyu Kong; Ruichen Zhao; Xinyue Chen; Yujia Zhai; Lixia Xiong
Journal:  Life (Basel)       Date:  2021-05-26

Review 9.  Long Non-Coding RNA HOTAIR in Breast Cancer Therapy.

Authors:  Monica Cantile; Maurizio Di Bonito; Margherita Cerrone; Francesca Collina; Michelino De Laurentiis; Gerardo Botti
Journal:  Cancers (Basel)       Date:  2020-05-09       Impact factor: 6.639

Review 10.  Exosomes and breast cancer drug resistance.

Authors:  Xingli Dong; Xupeng Bai; Jie Ni; Hao Zhang; Wei Duan; Peter Graham; Yong Li
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.